Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

End Of Aranesp, Procrit Pricing War Illustrates Inflationary Impact Of ASP

  • News

Executive Summary

Pricing constraints created by changes in Medicare Part B reimbursement may mean that segment growth will be the key driver for erythropoietin products going forward

You may also be interested in...



Avastin For Lung Cancer Will Be Free To Patients Who Beat The Average

Under a Genentech program that caps expenditures for Avastin, the oncologic will be free of charge to patients who continue using the therapy beyond the median duration of treatment for lung cancer

Avastin For Lung Cancer Will Be Free To Patients Who Beat The Average

Under a Genentech program that caps expenditures for Avastin, the oncologic will be free of charge to patients who continue using the therapy beyond the median duration of treatment for lung cancer

Private Payers Beginning To Adopt ASP-Based Reimbursement, Amgen Says

Private payers are beginning to adopt Medicare's average sales price-based methodology for drugs administered in the physician's office, Amgen said during a quarterly earnings call April 19

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS046855

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By